L · 0QLN.L
Tecan Group AG
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Männedorf 8708
- Website
- tecan.com
Price · as of 2024-12-31
$117.70
Market cap 1.7B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $131.80 | +11.98% |
| Intrinsic Value(DCF) | $87.76 | -25.44% |
| Graham-Dodd Method(GD) | $32.00 | -72.81% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $13.70 | $4.30 | |||
| 2011 | $30.00 | $40.70 | |||
| 2012 | $24.50 | $42.80 | |||
| 2013 | $24.70 | $28.60 | |||
| 2014 | $22.30 | $36.60 | |||
| 2015 | $34.30 | $84.30 | |||
| 2016 | $29.20 | $99.60 | |||
| 2017 | $189.37 | $175.98 | $75.08 | $38.30 | $86.50 |
| 2018 | $211.12 | $173.18 | $147.10 | $38.20 | $89.90 |
| 2019 | $272.89 | $181.29 | $34.79 | $40.20 | $86.70 |
| 2020 | $349.30 | $180.13 | $126.94 | $56.50 | $180.90 |
| 2021 | $338.06 | $267.83 | $460.80 | $49.80 | $338.80 |
| 2022 | $373.37 | $266.52 | $499.29 | $48.10 | $249.40 |
| 2023 | $359.85 | $228.90 | $6.72 | $54.40 | $21.30 |
| 2024 | $181.89 | $141.07 | $24.14 | $32.00 | $0.00 |
AI valuation
Our deep-learning model estimates Tecan Group AG's (0QLN.L) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $131.80
- Current price
- $117.70
- AI upside
- +11.98%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$87.76
-25.44% upside
Graham-Dodd
$32.00
-72.81% upside
Graham Formula
—
— upside
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions. It also develops and manufactures laboratory instrument manufacturers with essential components comprising precision pumps, valves, robotic arms, and developer software for life science research, diagnostics, and various other industries; Synergence, platform-based automation solution; and Freedom EVO and Fluent instruments. The company operates in Switzerland and Other European countries, North America, Asia, and internationally. Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.
- CEO
- Monica Manotas
- Employees
- 3.07K
- Beta
- 1.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($87.76 ÷ $117.70) − 1 = -25.44% (DCF, example).